ABSTRACT
We have developed a group of drugs, each consisting of a cell membrane disrupting lytic peptide (Hecate, Phor14 or Phor21) and a targeting moiety (LH/CG or LHRH) that effectively target and destroy human prostate and breast cancer cells in primary tumors and metastases in nude mice. These drugs cause necrosis of the cancer cells and have no known side effects, except inhibition of spermatogenesis in males and ovulation and corpus luteum formation in females. The activity of the drugs is highly correlated with the number of LH/CG or LHRH (GNRH) receptors expressed by the cancer cells. These drugs are highly effective in seeking out and destroying metastatic cells in bones, lungs, lymph glands and other organs. |